CMC Network |
A new cancer treatment which dramatically prolongs the survival period for the hepatocellular carcinoma(HCC) patients has been developed.
A faculty group from the The Catholic University of Korea Seoul St. Mary’s Hospital Comprehensive Cancer Institute’s, Seung Kew Yoon, Myeong Jun Song, Jong Young Choi, Si hyun Bae (Department of Internal Medicine, Division of Hepatology), and Ho Jong Chun (Department of Radiology) have studied a total of 129 patients, and the patients who underwent the new cancer treatment had much better chance of survival. Survival period was 7 months longer and the death rate was 3 times lower.
Transarterial chemoembolization (TACE) is a widely used treatment for HCC. The new treatment includes the usage of drug eluting beads to deliver chemotherapeutic drugs to destroy the tumor, referred to as drug-eluting bead (DC bead) TACE. This showed better treatment response than conventional TACE (cTACE) and delayed tumor progression. This is the first case in Korea with data to prove the sustainable effectiveness against cancer.
8 out of 10 patients have shown the effectiveness and 2 patients from out of them have been completely cured.